Home
HALO
HALO News

Latest Halozyme Therapeutics Inc. (HALO) News on January 7, 2025

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance

PR Newswire

18 hours ago

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance

Exploring 3 Prominent High Growth Tech Stocks In The United States

Simply Wall St.

6 days ago

Exploring 3 Prominent High Growth Tech Stocks In The United States

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks

8 days ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

PR Newswire

8 days ago

Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

PR Newswire

8 days ago

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications

PR Newswire

8 days ago

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Zacks

13 days ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Argus Research

14 days ago

HALO: Lowering target price to $58.00

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)

Zacks

15 days ago

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)

HALO or FOLD: Which Is the Better Value Stock Right Now?

Zacks

15 days ago

HALO or FOLD: Which Is the Better Value Stock Right Now?

Argus Research

20 days ago

HALO: Lowering target price to $60.00

How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08%

Zacks

22 days ago

How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08%

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

Zacks

22 days ago

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

Zacks

a month ago

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

Argus Research

a month ago

HALO: Raising target price to $61.00

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

Zacks

a month ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now?

Zacks

a month ago

Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now?

Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now

Zacks

a month ago

Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now

HALO vs. FOLD: Which Stock Is the Better Value Option?

Zacks

a month ago

HALO vs. FOLD: Which Stock Is the Better Value Option?

Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year?

Zacks

a month ago

Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year?

Argus Research

a month ago

HALO: Rating increased to a BUY

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

a month ago

Exploring Three High Growth Tech Stocks in the United States

Halozyme to Present at Upcoming Investor Conferences

PR Newswire

a month ago

Halozyme to Present at Upcoming Investor Conferences

Argus Research

a month ago

HALO: Rating decreased to a HOLD

HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up

Zacks

a month ago

HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up

MT Newswires

2 months ago

Sector Update: Health Care Stocks Rise Friday Afternoon

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Benzinga

2 months ago

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why

Zacks

2 months ago

Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

Zacks

2 months ago

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

Investing.com

2 months ago

Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal

MT Newswires

2 months ago

Sector Update: Health Care Stocks Advance Premarket Friday

MT Newswires

2 months ago

Update: Halozyme Therapeutics Withdraws Proposal to Acquire Evotec

MT Newswires

2 months ago

Sector Update: Health Care

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Zacks

2 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)

Zacks

2 months ago

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)

HALO vs. FOLD: Which Stock Should Value Investors Buy Now?

Zacks

2 months ago

HALO vs. FOLD: Which Stock Should Value Investors Buy Now?

Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now?

Zacks

2 months ago

Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now?

Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?

Zacks

2 months ago

Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

PR Newswire

2 months ago

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says

Bloomberg

2 months ago

Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

Benzinga

2 months ago

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

Zacks

2 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

Halozyme Submits $2.11 Billion Acquisition Offer For Evotec

MT Newswires

2 months ago

Halozyme Submits $2.11 Billion Acquisition Offer For Evotec

Investing.com

2 months ago

Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid

Halozyme bids for Evotec; BeiGene gets a new name

BioPharma Dive

2 months ago

Halozyme bids for Evotec; BeiGene gets a new name

Germany’s Evotec Gets Takeover Interest From Halozyme

Bloomberg

2 months ago

Germany’s Evotec Gets Takeover Interest From Halozyme

MT Newswires

2 months ago

Halozyme Proposes to Acquire Evotec for 11 Euros per Share

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

PR Newswire

2 months ago

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

Argus Research

2 months ago

HALO: Rating decreased to a HOLD

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today

Zacks

2 months ago

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today

Argus Research

2 months ago

HALO: What does Argus have to say about HALO?

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks

2 months ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Zacks

2 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Simply Wall St.

2 months ago

Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Top High Growth Tech Stocks To Watch In November 2024

Simply Wall St.

2 months ago

Top High Growth Tech Stocks To Watch In November 2024

Halozyme Announces Record Earnings, Guidance

FX Empire

2 months ago

Halozyme Announces Record Earnings, Guidance

HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up

Zacks

2 months ago

HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up

Halozyme Therapeutics Inc (HALO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com

2 months ago

Halozyme Therapeutics Inc (HALO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Halozyme Therapeutics (HALO) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks

2 months ago

Halozyme Therapeutics (HALO) Reports Q3 Earnings: What Key Metrics Have to Say

Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates

Zacks

2 months ago

Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates

MT Newswires

2 months ago

Halozyme Therapeutics Q3 Non-GAAP EPS, Revenue Increase

Associated Press Finance

2 months ago

Halozyme Therapeutics: Q3 Earnings Snapshot

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

PR Newswire

2 months ago

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

MT Newswires

2 months ago

Halozyme Therapeutics Says European Patent Office Revoked DARZALEX Patent

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

PR Newswire

2 months ago

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

Halozyme to Report Third Quarter 2024 Financial and Operating Results

PR Newswire

2 months ago

Halozyme to Report Third Quarter 2024 Financial and Operating Results

State Street Corp's Strategic Acquisition in Halozyme Therapeutics Inc

GuruFocus.com

3 months ago

State Street Corp's Strategic Acquisition in Halozyme Therapeutics Inc

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Zacks

3 months ago

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

MT Newswires

3 months ago

Halozyme Therapeutics Insider Sold Shares Worth $1,070,059, According to a Recent SEC Filing

Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options

Zacks

3 months ago

Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options

Argus Research

3 months ago

HALO: Lowering target price to $68.00

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks

3 months ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again

Zacks

3 months ago

Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again

MT Newswires

3 months ago

Wells Fargo Downgrades Halozyme Therapeutics to Equal Weight From Overweight, $62 Price Target

MT Newswires

3 months ago

Halozyme Therapeutics Expands Licensing Agreement With Argenx

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

PR Newswire

3 months ago

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

High Growth Tech Stocks In The United States To Watch

Simply Wall St.

3 months ago

High Growth Tech Stocks In The United States To Watch

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

3 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

MT Newswires

3 months ago

Halozyme Therapeutics Insider Sold Shares Worth $1,706,440, According to a Recent SEC Filing

MT Newswires

4 months ago

JPMorgan Downgrades Halozyme Therapeutics to Neutral From Overweight

FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech

Pharmaceutical Technology

4 months ago

FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech

MT Newswires

4 months ago

FDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis

PR Newswire

4 months ago

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis

MT Newswires

4 months ago

Halozyme Therapeutics Says FDA Approves Tecentriq Hybreza Cancer Immunotherapy

MT Newswires

4 months ago

Halozyme Therapeutics Insider Sold Shares Worth $1,773,790, According to a Recent SEC Filing

Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer

PR Newswire

4 months ago

Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks

4 months ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Thomson Reuters StreetEvents

4 months ago

Q1 2025 Avid Bioservices Inc Earnings Call

Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?

Zacks

4 months ago

Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?

Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?

Zacks

4 months ago

Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

Zacks

4 months ago

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

Halozyme to Present at Upcoming Investor Conferences

PR Newswire

4 months ago

Halozyme to Present at Upcoming Investor Conferences

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

4 months ago

Exploring Three High Growth Tech Stocks in the United States

Argus Research

4 months ago

HALO: Raising target price to $74.00

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Zacks

4 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Halozyme Earnings, Guidance Point to Bullish Future

FX Empire

4 months ago

Halozyme Earnings, Guidance Point to Bullish Future

MT Newswires

5 months ago

Halozyme Therapeutics Insider Sold Shares Worth $1,228,020, According to a Recent SEC Filing

Argus Research

5 months ago

HALO: Raising target price to $70.00

Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO)

GuruFocus.com

5 months ago

Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO)

MT Newswires

5 months ago

Halozyme Therapeutics Insider Sold Shares Worth $1,689,294, According to a Recent SEC Filing

Share on Social Networks: